Source-grounded facts extracted from Maze Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Maze Therapeutics, Inc. shareholders approved To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-08 meeting.
“Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm. Votes For Votes Against Abstentions Broker Non-Votes 44,557,778 728 101,523 0”
Maze Therapeutics, Inc. shareholders approved To elect each of Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as a Class I director to serve until the Company's 2029 annual meeting of stockholders at the 2026-06-08 meeting.
“Proposal 1: Election of Directors. Nominee Votes For Votes Withheld Broker Non-Votes Jason Coloma, Ph.D. 35,792,536 5,926,467 2,941,026 Neil Kumar, Ph.D. 34,056,425 7,662,578 2,941,026”
Misbah Tahir changed role as Chief Financial Officer and principal accounting officer at Maze Therapeutics, Inc..
“Misbah Tahir, the Company’s Chief Financial Officer, will be designated principal accounting officer following Ms. Bachrodt’s departure.”
Amy Bachrodt departed as Senior Vice President, Finance at Maze Therapeutics, Inc..
“On May 18, 2026, Amy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc. (the “Company”), effective June 1, 2026.”
Maze Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue $20.0 million, net income $24.2 million, EPS $0.45 per share.
“License Revenue: License revenue was $20.0 million for the quarter ended March 31, 2026. No license revenue was recognized for the quarter ended March 31, 2025.”
Maze Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.
“On March 25, 2026, Maze Therapeutics Inc. (the “Company”) issued a press release reporting its financial results for the fourth quarter and year ended December 31, 2025.”
Maze Therapeutics, Inc. incurred term loan of up to $200.0 million with Hercules Capital, Inc. at ‘prime rate’ as reported in the Wall Street Journal, with interest rate floors t maturing February 1, 2031.
“On February 4, 2026 (the “ Closing Date ”), Maze Therapeutics, Inc. (the “ Company ”) entered into that certain Loan and Security Agreement (the “ Hercules Loan Agreement ”), by and among the Company, as borrower, the lenders from time to time party thereto, and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the lenders party thereto, which provides for a senior secured term loan facility in an aggregate principal amount of up to $200.0 million”
Maze Therapeutics, Inc. entered into Loan and Security Agreement with Hercules Capital, Inc. valued at up to $200.0 million (effective 2026-02-04).
“On February 4, 2026 (the “ Closing Date ”), Maze Therapeutics, Inc. (the “ Company ”) entered into that certain Loan and Security Agreement (the “ Hercules Loan Agreement ”), by and among the Company, as borrower, the lenders from time to time party thereto, and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the lenders party thereto, which provides for a senior secured term loan facility in an aggregate principal amount of up to $200.0 million”
Maze Therapeutics, Inc. issued up to an aggregate of 5,231,090 shares of Common Stock of warrant to certain institutional and accredited investors for $16.249 per Pre-Funded Warrant.
“Placement ”) an aggregate of (i) 4,000,002 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $16.25 per share and (ii) in lieu of shares of Common Stock for certain Investors, pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to an aggregate of 5,231,090 shares of”
Maze Therapeutics, Inc. issued 4,000,002 shares of common stock to certain institutional and accredited investors for $16.25 per share.
“Placement ”) an aggregate of (i) 4,000,002 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $16.25 per share and (ii) in lieu of shares of Common Stock for certain Investors, pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to an aggregate of 5,231,090 shares of”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.